Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies

被引：0
|
作者：
Schreiber, S. [1 ]
Loftus, E. V., Jr. [2 ]
Maaser, C. [3 ]
Danese, S. [4 ,5 ]
Rudolph, C. [6 ]
Jongen, R. [6 ]
De Haas, A. [6 ]
Oortwijn, A. [6 ]
Vermeire, S. [7 ]
机构：
[1] Univ Kiel, Med 1, Kiel, Germany
[2] Mayo Clin, Coll Med & Sci, Div Gastroenterol & Hepatol, Rochester, MN USA
[3] Hosp Luneburg, Outpatients Dept Gastroenterol, Luneburg, Germany
[4] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
[5] San Raffaele Univ, Vita Salute, Milan, Italy
[6] Galapagos Nv, Leiden, Netherlands
[7] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP37
引用
收藏
页码：I085 / I087
页数：3
相关论文
共 50 条
  • [11] Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study
    Danese, S.
    Hibi, T.
    Ritter, T. E.
    Dinoso, J. B.
    Hsieh, J.
    Yun, C.
    Zhang, J.
    Zhao, S.
    Loftus, E. V., Jr.
    Rogler, G.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S034 - S035
  • [12] Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
    Matsuoka, K.
    Lowenberg, M.
    Fumery, M.
    Takatori, Y.
    Fujitani, Y.
    Oortwijn, A.
    Faes, M.
    Jamoul, C.
    Hibi, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I112 - I113
  • [13] Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE
    Schreiber, Stefan
    Rogler, Gerhard
    Watanabe, Mamoru
    Vermeire, Severine
    Maaser, Christian
    Danese, Silvio
    Faes, Margaux
    Van Hoek, Paul
    Hsieh, Jeremy
    Moerch, Ulrik
    Zhou, Yan
    de Haas, Angela
    Rudolph, Christine
    Oortwijn, Alessandra
    Loftus Jr, Edward V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (09) : 874 - 887
  • [14] SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: PHASE 2B/3 SELECTION STUDY AND LONGTERM EXTENSION RESULTS
    Morison, Ben
    Schreiber, Stefan
    Watanabe, Mamoru
    Yun, Chohee
    Zhou, Yan
    Zhao, Sally
    Hsieh, Jeremy
    Moerch, Ulrik
    Rogler, Gerhard
    Loftus, Edward V.
    GUT, 2021, 70 : A6 - A6
  • [15] RAPIDITY OF ULCERATIVE COLITIS SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION: PHASE 2B/3 SELECTION STUDY POST-HOC ANALYSIS
    Morison, Ben
    Danese, Silvio
    Hibi, Toshifumi
    Ritter, Timothy E.
    Dinoso, Jason B.
    Hsieh, Jeremy
    Yun, Chohee
    Zhang, Jie
    Zhao, Sally
    Loftus, Edward V.
    Rogler, Gerhard
    GUT, 2021, 70 : A93 - A93
  • [16] Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
    Loftus, E., Jr.
    Vermeire, S.
    Feagan, B.
    Yun, C.
    Hsieh, J.
    Liu, X.
    Zhao, S.
    Moerch, U.
    Sandborn, W. J.
    Hibi, T.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S112 - S113
  • [17] EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
    Peyrin-Biroulet, Laurent
    Loftus, Edward V.
    Danese, Silvio
    Vermeire, Severine
    Sandborn, William J.
    Fogel, Ronald P.
    Nijhawan, Sandeep
    Kempinski, Radoslaw
    Filip, Rafal
    Hospodarskyy, Ihor
    McNally, John
    Yun, Chohee
    Zhao, Sally
    Liu, Xiaopeng
    Tasset, Chantal T.
    Besuyen, Robin
    Watanabe, Mamoru
    Schreiber, Stefan
    Rogler, Gerhrad
    Hibi, Toshifumi
    Feagan, Brian G.
    GASTROENTEROLOGY, 2021, 160 (06) : S350 - S350
  • [18] EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
    Feagan, Brian G.
    Loftus, Edward V.
    Danese, Silvio
    Vermeire, Severine
    Sandborn, William J.
    Ritter, Timothy E.
    Mehta, Rajiv
    Seidler, Ursula
    Seibold, Frank
    Beales, Ian
    Kim, Hyo Jong
    McNally, John
    Yun, Chohee
    Zhao, Sally
    Liu, Xiaopeng
    Tasset, Chantal T.
    Besuyen, Robin
    Watanabe, Mamoru
    Schreiber, Stefan
    Rogler, Gerhard
    Hibi, Toshifumi
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2021, 160 (06) : S125 - S125
  • [19] Baseline disease severity of patients with Ulcerative Colitis influences rapid symptom relief under filgotinib treatment: post hoc analysis of the phase 2b/3 SELECTION study
    Saruta, M.
    Danese, S.
    Takatori, Y.
    Kaise, T.
    Rudolph, C.
    Ferrante, M.
    Hibi, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1506 - I1507
  • [20] Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
    Vermeire, S.
    Feagan, B.
    Peyrin-Biroulet, L.
    Oortwijn, A.
    Faes, M.
    de Haas, A.
    Rogler, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I473 - I474
12345